Clinical trials: Afib
Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
Safety and Effectiveness of the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial Fibrillation
This study will evaluate the safety and effectiveness of the Globe® Pulsed Field System for treating patients with symptomatic paroxysmal or persistent atrial fibrillation (AF).
- Trial name
- PULSAR (NCT05462145)
- Testing
- Globe Pulsed Field System
- Where
- 17 sites in United States, Canada and 2 more
- Volunteers
- 549 people
- Sponsor
- Kardium Inc.
Atrial Fibrillation (AF)
Study to Evaluate the effIcacy and Safety of Abelacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral Anticoagulation
This OLE part is an optional, single arm, multicenter, open-label extension (OLE) added to the core part to assess the long-term safety, tolerability, the incidence of ischemic stroke or SE and bleeding events of abelacimab in…
- Trial name
- LILAC-TIMI 76 (NCT07739888)
- Testing
- Abelacimab
- Volunteers
- 2,500 people
- Sponsor
- Novartis Pharmaceuticals
Atrial Fibrillation, Structural Heart Disease
Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease
Atrial fibrillation is an abnormal beating of the heart that can lead to stroke or heart failure. Structural heart diseases are conditions that affect the heart valves or heart muscle and can cause permanent heart damage if left…
- Trial name
- ECG-AID (NCT05442203)
- Testing
- Zio Patch Monitor, Echocardiogram
- Where
- 3 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Tempus AI
Atrial Fibrillation
A Phase III Study of Apixaban in Patients With Atrial Fibrillation
The purpose of this clinical research study is to determine whether apixaban is more effective than acetylsalicylic acid in the prevention of strokes associated with patients with atrial fibrillation.
- Trial name
- AVERROES (NCT00496769)
- Testing
- Apixaban, Acetylsalicylic acid
- Where
- 503 sites in United States, Argentina and 34 more
- Volunteers
- 6,421 people
- Sponsor
- Bristol-Myers Squibb
Atrial Fibrillation, Stroke
TRENDS: A Prospective Study of the Clinical Significance of Atrial Arrhythmias Detected by Implanted Device Diagnostics
The purpose of this study is to look at the heart rate and rhythm information collected daily in Medtronic implantable pulse generators (IPG), implantable cardioverter defibrillators (ICD) and cardiac resynchronization therapy…
- Conditions
- Atrial Fibrillation, Stroke, Heart Failure
- Trial name
- NCT00279981
- Testing
- Diagnostic
- Where
- 98 sites in United States, Australia and 1 more
- Volunteers
- 3,100 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Acute Coronary Syndromes
A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart
The purpose of this study is to determine if Apixaban is safer than a Vitamin K Antagonist given for 6 months in terms of bleeding in patients with an irregular heart beat (atrial fibrillation) and a recent heart attack or a…
- Trial name
- NCT02415400
- Testing
- Apixaban, vitamin K antagonist, Acetylsalicylic acid
- Where
- 626 sites in United States, Argentina and 35 more
- Volunteers
- 4,614 people
- Sponsor
- Bristol-Myers Squibb
Stroke, Prevention and Control
An Observational Cross-sectional Study Evaluating the Use of Re-sources and the Sociodemographic and Clinical Characteristics of Patients Diagnosed With Non-valvular Atrial Fibrillation With a Risk of Stroke or Systemic Embolism on Anticoagulant Therapy and Treated in Primary Care Centers
This is a retrospective observational study to describe the sociodemographic and clinical characteristics of patients diagnosed with non-valvular atrial fibrillation (NVAF) at risk of stroke or systemic embolism, who at least…
- Conditions
- Stroke, Prevention and Control, Atrial Fibrillation
- Trial name
- BRONCE-AP (NCT02559232)
- Testing
- Direct Oral Anticoagulant (DOAC)
- Where
- Spain
- Volunteers
- 247 people
- Sponsor
- Bayer
Paroxysmal Atrial Fibrillation
HeartLight Ablation in Patients With Paroxysmal Atrial Fibrillation (PAF)
The purpose of this study is to demonstrate the safety and effectiveness of the CardioFocus Endoscopic Ablation System with Adaptive Contact (HeartLight) in the treatment of atrial fibrillation by creating electrical isolation of…
- Trial name
- HeartLight (NCT01456000)
- Testing
- EAS-AC (HeartLight), Control Arm Ablation
- Where
- 21 sites in United States
- Volunteers
- 405 people
- Sponsor
- CardioFocus
Atrial Fibrillation
Detection of Atrial Fibrillation in Different Patient Target Groups Using the FibriCheck Smartphone Application
FibriCheck is a Conformité Européenne (CE)-approved (class IIa) medically diagnostic application that allows for heart rhythm registrations based on an optical signal captured via the smartphone camera.
- Trial name
- NCT03509493
- Testing
- FibriCheck
- Where
- 8 sites in Belgium
- Volunteers
- 465 people
- Sponsor
- Qompium NV
Atrial Fibrillation
Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
The objective is to evaluate whether once weekly subcutaneous (SC) injection of idrabiotaparinux sodium (biotinylated idraparinux) is at least as efficient to prevent clots in brain and in the other organs than oral international…
- Trial name
- BOREALIS-AF (NCT00580216)
- Testing
- Idrabiotaparinux sodium, Warfarin, Avidin
- Where
- 538 sites in United States, Argentina and 46 more
- Volunteers
- 3,773 people
- Sponsor
- Sanofi
Paroxysmal Atrial Fibrillation
ACT DiamondTemp TempeRAture-Controlled and Contact Sensing RF Ablation Clinical Trial for Atrial Fibrillation
The primary objective of this study is to establish the safety and performance effectiveness of the DiamondTemp System for the treatment of drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation (PAF).
- Trial name
- TRAC-AF (NCT02821351)
- Testing
- Radio frequency (RF) Cardiac ablation
- Where
- 4 sites in Czechia, France
- Volunteers
- 70 people
- Sponsor
- Medtronic Cardiac Ablation Solutions
Atrial Fibrillation, Heart Failure
Post Market Clinical Follow-up of CRT-DX Therapy With Lumax 640/740 HF-T
The study is designed to collect data of the performance and confirm the safety of the DX (Diagnostic eXtension) functionality in the Lumax 640/470 HF-T in patients with permanent atrial fibrillation and CRT-D indication…
- Trial name
- Pre-CRAFT (NCT01930695)
- Where
- 5 sites in Germany, Switzerland
- Volunteers
- 18 people
- Sponsor
- Biotronik SE & Co. KG
Atrial Fibrillation, Hypertension
Renal Nerve Denervation in Patients With Hypertension and Paroxysmal and Persistent Atrial Fibrillation
The purpose of this clinical study is to evaluate the feasibility of performing both renal nerve denervation and pulmonary vein isolation on the same patient with the intent of characterizing both safety and effectiveness in a…
- Trial name
- Symplicity AF (NCT02064764)
- Testing
- Symplicity Spyral™ Multi-Electrode Renal Denervation Catheter, Arctic Front Advance™ Cardiac Cryoablation System
- Where
- 10 sites in United States, Germany
- Volunteers
- 102 people
- Sponsor
- Medtronic Vascular
Atrial Fibrillation
Burden of Ischemic Stroke and Intake of Oral Anticoagulants in Patients With Atrial Fibrillation in the UK Primary Care
This study will characterize patients with ischemic stroke, a condition which occurs when a vessel supplying blood to the brain is obstructed, and a subpopulation of patients with irregular and often rapid heart rate (atrial…
- Trial name
- BEST-AF (NCT04099238)
- Testing
- Oral anticoagulant
- Where
- United Kingdom
- Volunteers
- 3,739 people
- Sponsor
- Bayer
Atrial Fibrillation
Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation
To evaluate the safety and tolerability of YM150 in subjects with non-valvular atrial fibrillation (NVAF)and to obtain information on pharmacokinetics and pharmacodynamics (anti-thrombotic potential) in the target population
- Trial name
- NCT00448214
- Testing
- YM150, warfarin
- Where
- 18 sites in Australia, Hong Kong and 8 more
- Volunteers
- 448 people
- Sponsor
- Astellas Pharma Inc
Atrial Fibrillation
Burden of Illness in Atrial Fibrillation
The overall goal of this retrospective registry study is to investigate the burden-of.illness in atrial fibrillation (AF) in Denmark.
- Trial name
- NCT02615587
- Testing
- Standard of care in AF in Denmark
- Where
- Denmark
- Volunteers
- 107,532 people
- Sponsor
- Bayer
Paroxysmal AF
AblaView® Unipolar PFA OCR-guided Feasibility Study - First in Man
Exploratory Clinical Investigation to evaluate the feasibility and safety of the AblaView® Unipolar Percutaneous Ablation Irrigated Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation using Polarization…
- Trial name
- NCT06700226
- Testing
- AblaView® Unipolar PFA System
- Where
- Uzbekistan
- Volunteers
- 10 people
- Sponsor
- Medlumics
Atrial Fibrillation
Pulmonary Vein Ablation Versus Amiodarone in the Elderly
The purpose of the study is to demonstrate that in patients of 70 years or older with symptomatic paroxysmal atrial fibrillation (AF) pulmonary vein isolation (PVI) using RF ablation therapy is superior to medical treatment with…
- Trial name
- PAVANE (NCT01276093)
- Testing
- PVI ablation, Amiodarone
- Where
- 6 sites in Netherlands
- Volunteers
- 59 people
- Sponsor
- Abbott Medical Devices
Atrial Fibrillation
A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation
A randomized, placebo-controlled, participant-and investigator-blinded study to evaluate the efficacy in reducing atrial fibrillation burden as well as the safety, tolerability and pharmacokinetics of PKN605 in participants with…
- Trial name
- NCT07217067
- Testing
- PKN605
- Where
- 40 sites in United States, Canada and 5 more
- Volunteers
- 165 people
- Sponsor
- Novartis Pharmaceuticals
Atrial Fibrillation, Atrial Flutter
EURopean Trial In Atrial Fibrillation(AF) or Flutter (AFL) Patients Receiving Dronedarone for the maIntenance of Sinus Rhythm (EURIDIS)
To assess the efficacy of dronedarone versus placebo for the maintenance of normal sinus rhythm after electrical, pharmacological or spontaneous conversion of atrial fibrillation/atrial flutter (AF/AFL).
- Trial name
- EURIDIS (NCT00259428)
- Testing
- Dronedarone (SR33589)
- Where
- 12 sites in Belgium, Czechia and 10 more
- Volunteers
- 615 people
- Sponsor
- Sanofi